Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (2) : 115-117     DOI: 10.1007/s11684-011-0112-3
NEWS AND VIEWS |
Metformin for cancer prevention
Yonghua Yang()
School of Pharmacy, Fudan University, Shanghai 201203, China
Download: PDF(70 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Corresponding Authors: Yang Yonghua,Email:yonghuayang@hotmail.com   
Issue Date: 05 June 2011
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-011-0112-3     OR     http://academic.hep.com.cn/fmd/EN/Y2011/V5/I2/115
Fig.1  Effects of metformin on ACF. The mean number of rectal ACF per patient decreased significantly at 1 month (versus at baseline) in the metformin group. In contrast, the mean number of ACF per patient remained similar at 1 month (versus at baseline) in the control group. Data are presented in a box-and-whisker plot. Each box includes the mean of all results falling between the 25th and 75th percentiles, and the median value is represented as a horizontal line inside each box. ACF: aberrant crypt foci.
1 Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27(25): 3576–3586
doi: 10.1038/sj.onc.1211024 pmid:18212742
2 Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab 2003; 29(4 Pt 2): 6S36–43
3 Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010; 3(9): 1060–1065
doi: 10.1158/1940-6207.CAPR-10-0175 pmid:20810670
4 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304–1305
doi: 10.1136/bmj.38415.708634.F7 pmid:15849206
5 Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137(2): 482–488
doi: 10.1053/j.gastro.2009.04.013 pmid:19375425
6 Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506–2511
doi: 10.3748/wjg.15.2506 pmid:19469001
7 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52(9): 1766–1777
doi: 10.1007/s00125-009-1440-6 pmid:19572116
8 Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008; 1(5): 369–375
doi: 10.1158/1940-6207.CAPR-08-0081 pmid:19138981
9 Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67(22): 10804–10812
doi: 10.1158/0008-5472.CAN-07-2310 pmid:18006825
10 Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen—induced lung tumorigenesis. Cancer Prev Res (Phila) 2010; 3(9): 1066–1076
doi: 10.1158/1940-6207.CAPR-10-0055 pmid:20810672
11 Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008; 99(11): 2136–2141
doi: 10.1111/j.1349-7006.2008.00933.x pmid:18803638
12 Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) , 2010, 3(9): 1077–1083
doi: 10.1158/1940-6207.CAPR-10-0186 pmid:20810669
13 Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 2010; 651(1–3): 41–50
14 Hirsch HA, Iliopoulos D, Tsichlis P N, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69(19): 7507–7511
doi: 10.1158/0008-5472.CAN-09-2994 pmid:19752085
15 Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009; 106(10): 3907–3912
doi: 10.1073/pnas.0807991106 pmid:19237574
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed